Alvotech provides u.s. regulatory update on avt02, a high-concentration interchangeable biosimilar candidate to humira® (adalimumab)

Reykjavik, iceland, sept. 20, 2023 (globe newswire) -- alvotech (nasdaq: alvo, or the “company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the u.s. food and drug administration (fda) has accepted alvotech's resubmitted biologics license application (bla) for avt02, a high-concentration, interchangeable biosimilar candidate to humira® (adalimumab). the fda has also announced a biosimilar user fee act (bsufa) goal date for approval of the resubmitted avt02 bla.
ALVO Ratings Summary
ALVO Quant Ranking